Welcome to our dedicated page for ImmunityBio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.
ImmunityBio, Inc. (symbol: IBRX) is a pioneering biotechnology company specializing in immuno-oncology and infectious disease treatments. With a focus on activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems, ImmunityBio is at the forefront of developing innovative molecular and product platforms.
The company's key platforms include the development of antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies. ImmunityBio is working on several significant product candidates, such as n-803, aldoxorubicin, and a second-generation adenovirus vector. These platforms are designed to activate natural killer (NK) cells, T cells, tumoricidal macrophages, and memory T cells, providing a comprehensive approach to cancer treatment and infectious disease management.
Anktiva, one of ImmunityBio's leading product candidates, is an IL-15 superagonist antibody-cytokine fusion protein, which enhances the body's immune response against cancer cells. The company's pipeline includes treatments targeting bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).
Headquartered in the United States, ImmunityBio operates across two geographical segments: the United States and Europe, with key revenue generated from European markets. The company is integrated from discovery and development to commercialization, ensuring a seamless transition of its products from the laboratory to the market.
ImmunityBio has achieved several milestones, including the initiation of pivotal clinical trials and strategic partnerships with leading research institutions. These accomplishments underscore the company's commitment to transforming the landscape of immuno-oncology and infectious disease treatment.
Stay informed about ImmunityBio's latest developments, financial performance, and upcoming projects by visiting our news section regularly.
ImmunityBio has announced the initiation of a Phase 2b clinical trial for its investigational Tri-Ad5 cancer vaccine, which combines three vaccines with the IL-15 superagonist N-803. This trial aims to assess the effectiveness of this combination in preventing colorectal and other cancers in individuals with Lynch syndrome, a hereditary condition increasing cancer risks. The study will enroll 186 participants across 14 U.S. centers, marking a significant advancement in Lynch syndrome research. Lynch syndrome, which affects about 1 in 300 people, can lead to multiple cancers at a younger age. The Tri-Ad5 vaccines target specific cancer-associated proteins and are designed to enhance immune response.
ImmunityBio, Inc. (NASDAQ: IBRX) announces that Executive Chairman Patrick Soon-Shiong, M.D., will deliver the 2023 David Packard Award Lecture at the Uniformed Services University in Bethesda, MD, on April 25. This lecture recognizes his pioneering contributions to cancer therapies and immunotherapy, specifically discussing the activation of natural killer and T cells for cancer treatment. Dr. Soon-Shiong's illustrious career includes significant achievements in immunology and over 500 patents. He founded American Pharmaceutical Partners and developed Abraxane, a groundbreaking chemotherapy drug. The lecture is part of an annual event honoring David Packard, a key figure in U.S. defense and education. ImmunityBio focuses on developing advanced immunotherapies for cancer and infectious diseases.
ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Karim Chamie from UCLA will present findings from the QUILT 3.032 study at the ASCO GU conference in San Francisco from February 16-18. This study assesses the quality of life for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving N-803 combined with BCG. Results showed improved physical function among responders and highlighted a favorable risk/benefit ratio. The FDA is reviewing the Biologics License Application for N-803, with a PDUFA date set for May 23, 2023.
FAQ
What is the current stock price of ImmunityBio (IBRX)?
What is the market cap of ImmunityBio (IBRX)?
What does ImmunityBio, Inc. specialize in?
What are the key product candidates of ImmunityBio?
Which cancers does ImmunityBio focus on treating?
What geographical segments does ImmunityBio operate in?
What types of therapies is ImmunityBio developing?
How does ImmunityBio's Anktiva work?
What recent achievements has ImmunityBio made?
Where can I find the latest news about ImmunityBio?
What is ImmunityBio's business model?